Home › Funds › Propel Bio Management, LLC › KYTX

Propel Bio Management, LLC position in KYTX

KYVERNA THERAPEUTICS INC · Health Care

Propel Bio Management, LLC reported holding 700,595 shares of KYTX (KYVERNA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$4.8M, representing 2.53% of its reported portfolio and ranking #14 among its reported holdings. Propel Bio Management, LLC has disclosed KYTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)700.60K sh
Reported value held$4.76M
Portfolio Weight2.53%
First reportedQ4 2025
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Propel Bio Management, LLC's KYTX position evolved

Propel Bio Management, LLC first disclosed a stake in KYTX in Q4 2025 at 666,666 shares (US$6.3M). The position peaked in Q2 2026 at 883,198 shares, worth US$7.9M. Across 4 filings, Propel Bio Management, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 700,595 shares valued at US$4.8M — a reduction of -182,603 shares quarter over quarter.. Notable position changes include a 37% increase in Q2 2026 (shares fell 24% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 666.67K $6.27M New
Q1 2026 644.42K $5.59M Reduce
Q2 2026 883.20K $7.87M Add
Q3 2026 700.60K $4.76M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KYTX and 13F data

KYTX (KYVERNA THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in KYTX — the largest reported positions include GordonMD Global Investments LP (US$37.8M), GILEAD SCIENCES, INC. (US$28.1M), Bain Capital Life Sciences Investors, LLC (US$25.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KYTX

All KYTX fund holders →

FAQ

How long has Propel Bio Management, LLC held KYTX?

Propel Bio Management, LLC has disclosed KYTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Propel Bio Management, LLC's current position in KYTX?

As of Q3 2026, Propel Bio Management, LLC holds 700.60K shares of KYTX (KYVERNA THERAPEUTICS INC), valued at $4.76M, representing 2.53% of its reported portfolio and ranking #14.

Has Propel Bio Management, LLC been buying or selling KYTX?

In the latest 13F filing (Q3 2026), Propel Bio Management, LLC reduced its position in KYTX. The position peaked in Q2 2026 at 883.20K shares.

Which other funds hold KYTX?

Other major institutional holders of KYTX include GordonMD Global Investments LP, GILEAD SCIENCES, INC., Bain Capital Life Sciences Investors, LLC, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.